Stockscreener 앱 받기
6.84
3.64%
0.24
시간 외 거래:
6.84
전일 마감가:
$6.60
열려 있는:
$6.65
하루 거래량:
11.44M
Relative Volume:
4.82
시가총액:
$1.07B
수익:
$181.41M
순이익/손실:
$-59.56M
주가수익비율:
-16.29
EPS:
-0.42
순현금흐름:
$-38.83M
1주 성능:
+27.14%
1개월 성능:
+43.40%
6개월 성능:
+92.68%
1년 성능:
+206.73%
1일 변동 폭
$6.54
$6.93
1주일 범위
$5.25
$7.085
52주 변동 폭
$2.21
$7.085
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
명칭
Xeris Biopharma Holdings Inc
전화
844-445-5704
주소
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
XERS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
6.84 | 879.25M | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2023-08-28 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Craig Hallum | Buy |
| 2021-11-17 | 개시 | SVB Leerink | Outperform |
| 2021-10-29 | 개시 | H.C. Wainwright | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-02-18 | 개시 | Piper Sandler | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Leerink Partners | Outperform |
| 2018-07-16 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Xeris Biopharma Holdings Inc 주식(XERS)의 최신 뉴스
How liquid is Xeris Biopharma Holdings Inc. stockSpeedy Gain Trade Picks - thegnnews.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st
Wyckoff Accumulation Phase Possible in Xeris Biopharma Holdings Inc.Potential Breakout Stock List Published This Week - beatles.ru
Xeris Biopharma Holdings Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2025 Earnings Call Transcript - Insider Monkey
XERS (Xeris Biopharma Holdings) Momentum Rank : 3 (As of Aug. 08, 2025) - GuruFocus
XERS Crosses Above Average Analyst Target - Nasdaq
Xeris Biopharma Reports Strong Q2 2025 Results - TipRanks
Beyond the Balance Sheet: What SWOT Reveals About Xeris Biopharm - GuruFocus
Xeris raises 2025 revenue guidance to $280M–$290M following 49% Q2 growth, led by Recorlev - MSN
Xeris Biopharma Holdings, Inc. SEC 10-Q Report - TradingView
Xeris Biopharma: Q2 Earnings Snapshot - The Washington Post
Xeris Biopharma Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Little Excitement Around Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Revenues - 富途牛牛
Xeris (XERS) Q2 Revenue Jumps 49% - The Motley Fool
Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Xeris Biopharma shares rise 24.23% premarket after beating Q2 revenue expectations and raising FY guidance. - AInvest
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance - BioSpace
Earnings Flash (XERS) Xeris Biopharma Posts Q2 Net Loss $0.01 a Share, vs. FactSet Est of $0.05 Loss - MarketScreener
Xeris Biopharma beats Q2 revenue expectations, raises FY guidance - MarketScreener
Institutional scanner results for Xeris Biopharma Holdings Inc.Trade Flow Monitor with Volume Tracker - Newser
Can trapped investors hope for a rebound in Xeris Biopharma Holdings Inc.Conservative Asset Allocation Risk Analysis - Newser
Xeris Biopharma Holdings Inc. stock trend outlook and recovery pathSmart Trend Analysis With Buy Point Cues - Newser
Is Xeris Biopharma Holdings Inc. building a consolidation baseBuy Alert Based on RSI and Volume - Newser
Xeris Pharmaceuticals Receives Buy Rating from Craig-Hallum, Analyst Consensus Remains Strong Buy with $6.00 Average Price Target. - AInvest
What are the technical indicators suggesting about Xeris Biopharma Holdings Inc.Sky-high return potential - Jammu Links News
Is Xeris Biopharma Holdings Inc. a good long term investmentOverwhelming financial success - Jammu Links News
Why is Xeris Biopharma Holdings Inc. stock attracting strong analyst attentionAchieve explosive financial results today - Jammu Links News
What catalysts could drive Xeris Biopharma Holdings Inc. stock higher in 2025Capitalize on fast-growing stocks today - Jammu Links News
Is Xeris Biopharma Holdings Inc. a growth stock or a value stockAchieve impressive returns with smart timing - Jammu Links News
Should I hold or sell Xeris Biopharma Holdings Inc. stock in 2025Get exclusive access to professional stock picks - Jammu Links News
Xeris Biopharma Holdings Inc. Stock Support and Resistance Levels You Should KnowEarnings Based Stock Performance Forecast - Newser
When is Xeris Biopharma Holdings Inc. stock expected to show significant growthPost Market Recommendation For 2025 - Jammu Links News
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025 - BioSpace
Why Xeris Biopharma Holdings Inc. stock attracts strong analyst attentionTrading Watchlist with Real Time Filters - Newser
What is Xeris Biopharma Holdings Inc. company’s growth strategyMarket Forecast Alerts Backed By Experts - Jammu Links News
How strong is Xeris Biopharma Holdings Inc. company’s balance sheetStock Strategy Trend Scanner For Every Investor - Jammu Links News
What makes Xeris Biopharma Holdings Inc. stock price move sharplyProfitable Trading Blueprint with Entry Zones - Newser
Key External Factors That Drive Xeris Biopharma Holdings Inc. Stock Price MovementsHigh Yield Stock Screening Results Explained - metal.it
Xeris Biopharma Holdings Inc (XERS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):